國立虎尾科技大學 |

Essays on the Economics of Health Care and Innovation.

Record Type:	Language materials, manuscript : Monograph/item
Title/Author:	Essays on the Economics of Health Care and Innovation./
Author:	Berger, Benjamin Arthur.
Description:	1 online resource (161 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 85-12, Section: B.
Contained By:	Dissertations Abstracts International85-12B.
Subject:	Public policy. -
Online resource:	click for full text (PQDT)
ISBN:	9798382777474

Essays on the Economics of Health Care and Innovation.
Berger, Benjamin Arthur.

Essays on the Economics of Health Care and Innovation. - 1 online resource (161 pages)

Source: Dissertations Abstracts International, Volume: 85-12, Section: B.

Thesis (Ph.D.)--Harvard University, 2024.

Includes bibliographical references

In this dissertation, I use tools from economics to study policies that affect patient access in biopharmaceutical markets. In Chapter 1, I analyze how hospitals and health systems respond to the 340B Drug Pricing Program, a US federal policy that requires biopharmaceutical companies to give discounts on prescription drugs to certain hospitals. I show that only hospitals in integrated health systems increase billing for cancer drugs in response to 340B participation and provide additional evidence that this is related to restructuring of relationships among system providers. In Chapter 2, my coauthors and I explore how patients respond to FDA approval of new uses for previously approved drugs, which we term follow-on indications. We show that patients respond to approval by increasing utilization even though physicians were already free to prescribe medications for the newly approved uses. Patients respond more strongly to indication approvals that are novel, including approvals of indications for new diseases or disease areas. These results point to follow-on indication approvals substantially reducing uncertainty about the value of medications and effectively increasing patient access. Lastly, in Chapter 3, I consider the impacts of the Orphan Drug Credit, a tax incentive for R&D spending on clinical rare disease drug development. I find that reducing the credit resulted in a modest decline in employment of US sites for rare disease clinical trials but no significant reduction in clinical trials for rare diseases.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2024

Mode of access: World Wide Web

ISBN: 9798382777474Subjects--Topical Terms:

1002398
Public policy.
Subjects--Index Terms:

Food and Drug AdministrationIndex Terms--Genre/Form:

554714
Electronic books.

Essays on the Economics of Health Care and Innovation.
LDR:02936ntm a22004097 4500 001 1152767
005 20241213095555.5
006 m o d
007 cr mn ---uuuuu
008 250605s2024 xx obm 000 0 eng d
020 $a 9798382777474
035 $a (MiAaPQ)AAI31295241
035 $a AAI31295241
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Berger, Benjamin Arthur. $3 1479852
245 1 0 $a Essays on the Economics of Health Care and Innovation.
264 0 $c 2024
300 $a 1 online resource (161 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-12, Section: B.
500 $a Advisor: Chandra, Amitabh;Shepard, Mark.
502 $a Thesis (Ph.D.)--Harvard University, 2024.
504 $a Includes bibliographical references
520 $a In this dissertation, I use tools from economics to study policies that affect patient access in biopharmaceutical markets. In Chapter 1, I analyze how hospitals and health systems respond to the 340B Drug Pricing Program, a US federal policy that requires biopharmaceutical companies to give discounts on prescription drugs to certain hospitals. I show that only hospitals in integrated health systems increase billing for cancer drugs in response to 340B participation and provide additional evidence that this is related to restructuring of relationships among system providers. In Chapter 2, my coauthors and I explore how patients respond to FDA approval of new uses for previously approved drugs, which we term follow-on indications. We show that patients respond to approval by increasing utilization even though physicians were already free to prescribe medications for the newly approved uses. Patients respond more strongly to indication approvals that are novel, including approvals of indications for new diseases or disease areas. These results point to follow-on indication approvals substantially reducing uncertainty about the value of medications and effectively increasing patient access. Lastly, in Chapter 3, I consider the impacts of the Orphan Drug Credit, a tax incentive for R&D spending on clinical rare disease drug development. I find that reducing the credit resulted in a modest decline in employment of US sites for rare disease clinical trials but no significant reduction in clinical trials for rare diseases.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2024
538 $a Mode of access: World Wide Web
650 4 $a Public policy. $3 1002398
653 $a Food and Drug Administration
653 $a Health economics
653 $a Orphan drugs
653 $a Pharmaceutical policy
653 $a Rare diseases
655 7 $a Electronic books. $2 local $3 554714
690 $a 0501
690 $a 0769
690 $a 0511
690 $a 0630
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a Harvard University. $b Public Policy. $3 1189378
773 0 $t Dissertations Abstracts International $g 85-12B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31295241 $z click for full text (PQDT)